hMAM联合MMP-9和C-erbB2 mRNA表达检测在乳腺癌外周血微转移诊断中的应用

doi:10.13481/j.1671-587x.20170528

摘要/Abstract

摘要： 目的：探讨生物标记物人乳腺珠蛋白（hMAM）联合基质金属蛋白酶9（MMP-9）和人表皮生长因子受体2（C-erbB2） mRNA在乳腺癌外周血微转移患者中阳性表达情况，阐明其用于诊断乳腺癌外周血微转移的临床应用价值。方法：选择74例乳腺癌患者、21例乳腺纤维腺瘤患者和10名健康人作为研究对象，所有患者均行手术治疗，采集外周血，运用实时荧光定量PCR检测外周血hMAM、MMP-9和C-erbB2 mRAN表达水平，比较hMAM、MMP-9和C-erbB2联合检测阳性表达率，并分析不同临床病理特征患者之间hMAM、MMP-9和C-erbB2联合检测的差异。结果：MMP-9、C-erbB2 mRNA阳性表达率在有无淋巴结转移患者间比较差异有统计学意义（χ²=6.450，P < 0.05；χ²=5.636，P < 0.05），hMAM mRNA阳性表达率在HER-2阳性与阴性患者间比较差异有统计学意义（χ²=5.804，P < 0.05）。乳腺癌患者hMAM及联合MMP-9和C-erbB2 mRNA阳性表达率分别为37.84%（28/74）、59.46%（44/74）和48.65%（36/74），三者联合阳性表达率为64.86%（48/74），均高于健康对照组（χ²=5.676，P < 0.05；χ²=3.102，P > 0.05；χ²=5.339，P < 0.05；χ²=2.310，P > 0.05）、乳腺纤维腺瘤组（χ²=8.438，P < 0.01；χ²=4.491，P < 0.05；χ²=7.982，P < 0.01；χ²=4.844，P < 0.05）和非乳腺癌组（对照组+乳腺纤维腺瘤组）（χ²=13.093，P < 0.01；χ²=6.471，P < 0.05；χ²=11.837，P < 0.01；χ²=6.103，P < 0.05）。与Ⅰ+Ⅱ期比较，Ⅲ+Ⅳ期乳腺患者hMAM mRNA单独及联合阳性表达率均增加，其中hMAM mRNA单独及联合C-erbB2 mRNA阳性表达率比较差异有统计学意义（χ²=5.157，P < 0.05；χ²=4.912，P < 0.05）。结论：hMAM诊断乳腺癌微转移的阳性率较低，联合MMP-9和C-erbB2 mRNA检测可以提高诊断阳性率，对于早期乳腺癌微转移诊断具有一定临床应用价值。

关键词: 乳腺肿瘤, 微转移, 人乳腺珠蛋白, 基质金属蛋白酶9, 人表皮生长因子受体2

Abstract: Objective: To explore the positive expressions of biological markers human mammaglobin(hMAM)combined with matrix metallopeptidase 9(MMP-9) and human epidermal growth factor receptor 2(C-erbB2)mRNA in peripheral blood of the breast cancer patients with micrometastases,and to clarify its clinical application value in diagnosis of the micrometastases in peripheral blood of the breast cancer patients. Methods: A total of 74 patients with breast cancer,21 patients with breast fibroadenoma and 10 healthy controls were selected as the subjects. All the patients received surgical treatment and the peripheral blood was collected.The mRNA expression levels of hMAM,MMP-9 and C-erbB2 in peripheral blood were measured by the real-time fluorescent quantitative PCR.The positive expression rates of detection of hMAM,MMP-9 and C-erbB2 were compared,and the differences in detection of hMAM combined with MMP-9 and C-erbB2 between the patients with different clinicopathologic features were analyzed. Results: In the breast cancer patients with lymph node metastasis,the differences of positive expression rates ofMMP-9 and C-erbB2 mRNA were significant(χ²=6.450, P<0.05;χ²=5.636, P<0.05),and the difference of positive expression rate of hMAM mRNA was sigificant between HER-2 positive and negative patients(χ²=5.804, P<0.05).The positive expression rates ofindividualhMAM and combined with MMP-9 and C-erbB2 were 37.84%(28/74),59.46%(44/74)and 48.65%(36/74)in the breast cancer patients,the combined postive expression rate of these three kinds of markers was 64.86%(48/74),which were higher than those in healthy controls group(χ²=5.676,P<0.05;χ²=3.102,P>0.05;χ²=5.339,P<0.05;χ²=2.310,P>0.05),fibroadenoma ofbreast group(χ²=8.438, P<0.01; χ²=4.491, P<0.05; χ²=7.982, P<0.01; χ²=4.844, P<0.05)and non-breast cancer group(healthy controls group+ breast fibroadenoma group)(χ²=13.093, P<0.01; χ²=6.471, P<0.05; χ²=11.837, P<0.01;χ²=6.103, P<0.05).The positive expression rates ofindividualhMAM and the joint detection in the breast cancer patients at stage Ⅲ+Ⅳ were higher than those in the patients at stageⅠ+Ⅱ;the positive expression rates of individualhMAM and combined with C-erbB2 were statistically significant(χ²=5.157, P<0.05; χ²=4.912, P<0.05). Conclusion: hMAM has a low positive rate in the diagnosis of micrometastases in the breast cancer patients,while hMAM combined with MMP-9 and C-erbB2 detectioncould improve the positive rates.which presents some clinical application value for the early diagnosis of breast cancer micrometastases.

Key words: breast neoplasms, micrometastases, human mammaglobin, matrix metallopeptidase 9, human epidermal growth factor receptor 2

中图分类号:

R737.9

于秀艳, 张晓伟, 野丽莉, 李铤, 刘晓峰, 吴雪峰. hMAM联合MMP-9和C-erbB2 mRNA表达检测在乳腺癌外周血微转移诊断中的应用[J]. 吉林大学学报(医学版), 2017, 43(05): 1009-1014.

YU Xiuyan, ZHANG Xiaowei, YE Lili, LI Ting, LIU Xiaofeng, WU Xuefeng. Application of detection of expressions of hMAM combined with MMP-9 and C-erbB2 mRNA in peripheral blood in diagnosis of micrometastases of breast cancer[J]. Journal of Jilin University Medicine Edition, 2017, 43(05): 1009-1014.

参考文献

[1] Watson MA,Fleming TP.Mammaglobin,a mammary specific member of the uteroglobin gene family is overexpressed in human breast cancer[J].Cancer Res,1996,56(4):860-865.
[2] Becker RM,Darrow C,Zimonjie DB,et al.Identification of mammaglobin B,a novel member of the uteroglobin gene family[J].Genomies,1998,54(1):70-78.
[3] Li C, Zhang T.Human mammaglobin:A specific marker for breast cancer prognosis[J].J BUON,2016,21(1):35-41.
[4] 陈月凤,杨华伟,莫钦国,等.CK19和hMAM及SBEM检测乳腺癌微转移价值分析[J].中华肿瘤防治杂志,2014(3):198-202.
[5] Bozhenko VK,Kharchenko NV,Vaskevich EF,et al.Mammaglobin in peripheral blood and tumor in breast cancer patients[J].Biomed Khim,2016,62(4):453-457.
[6] Bölke E,Orth K,Gerber PA,et al.Gene expression of circulating tumour cells in breast cancer patients[J].Eur J Med Res,2009,14(10):426-432.
[7] 鲍慧铮,陈力,李思莹,等.CKl9联合hMAM检测乳腺癌循环肿瘤细胞的临床价值[J].肿瘤,2014(2):153-157.
[8] Livak KJ,Schmittgen TD.Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T) method[J].Methods,2001,25(4):402-408.
[9] 杨超,康炜,李建华,等.血清乳腺珠蛋白与乳腺癌的相关性及临床意义探讨[J]. 检验医学,2014,29(1):61-64.
[10] 印滇,王亚非,杨莉,等.hMAM水平与乳腺癌早期诊断和癌微转移的相关性及临床意义研究[J].临床和实验医学杂志,2015,14(18):1512-1515.
[11] GoedegebuurePS,Watson MA,Carsten T,et al.Mammaglobin-based strategies for treatment of breast cancer[J].Curr Cancer Drug Targets,2017,4(6):531-542.
[12] Al Joudi FS.Human mammaglobin in breast cancer:a brief review of its clinical utility[J].Indian J Med Res,2014,139(5):675-685.
[13] Marchetti A,Buttitta F,Bertacca G,et al.mRNA markers of breast cancer nodal metastases:comparision between mammaglobin and carcinoembryonic antigen in 248 patients[J].J Pathol,2001,195(2):186-190.
[14] Chen Y,Zou TN,Wu ZP,et al.Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigen-positive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer[J].Int J Biol Markers,2010,25(2):59-68.
[15] Koh EH,Cho YW,Mun YJ,et al.Upregulation of human mammaglobin reduces migration and invasion of breast cancer cells[J].Cancer Invest,2014,32(1):22-29.
[16] Candido S,Abrams SL,Steelman LS,et al.Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy[J].Biochim Biophys Acta,2016,1863(3):438-448.
[17] 张弘,姜义,关文曾,等.乳腺癌组织中基质金属蛋白酶2、9活性的测定[J].吉林大学学报:医学版,2002,28(6):591-599.
[18] 孙亚楠,毛晓韵,刘晓虹,等.基底细胞样乳腺癌患者乳腺癌和癌旁正常乳腺组织中MTDH与MMP-9蛋白表达的相关性[J].吉林大学学报:医学版,2016,42(3):530-534,639.
[19] Browne BC,O'Brien N,Duffy MJ,et al.HER-2 signaling and inhibition in breast cancer[J].Curr Cancer Drug Targets,2009,9(3):419-438.
[20] 吴娜萍,肇毅,王珏,等.联合多标志物检测乳腺癌外周血循环肿瘤细胞与分子分型的相关性及临床意义[J].中华实验外科杂志,2014,(5):935-937.
[21] 颜蕴文,张敬杰,徐晓军,等.联合检测乳腺癌患者外周血中细胞角蛋白19及人乳腺球蛋白mRNA的意义[J].中华乳腺病杂志:电子版,2010(2):45.
[22] 葛明广.荧光定量PCR法检测人乳腺珠蛋白与乳腺癌微小转移诊断的研究[J].中外医疗,2008(28):25-27.
[23] Roncella S,Ferro P,Bacigalupo B,et al.Human mammaglobin mRNA is a reliable molecular marker for detecting occult breast cancer cells in peripheral blood[J].J Exp Clin Cancer Res,2005,24(2):265-271.
[24] Lin YC,Wu Chou YH,Liao IC,et al.The expression of mammaglobin mRNA in peripheral blood of metastatic breast cancer patients as an adjunct to serum tumor markers[J].Cancer Lett,2003,191(1):93-99.
[25] Liu Y,Ma L,Liu X,et al.Expression of human mammaglobin as a marker of bone marrow micrometastasis in breast cancer[J].Exp Ther Med,2012,3(3):550-554.
[26] Lee GW,Kim JY,Koh EH,et al.Plasma human mammaglobin mRNA associated with poor outcome in patients with breast cancer[J].Genet Mol Res,2012,11(4):4034-4042.